Biological E. will be Intercell's strategic partner for marketing and selling the Japanese Encephalitis vaccine in certain Asian countries. Under the terms of the agreement, Biological E. will manufacture the product in India for the Asian endemic market. Intercell AG and Biological E anticipate that they will broaden their strategic alliance by collaborating on the development of future vaccines by combining the strength of Intercell’s Antigen
Identification Program in identifying new, protective antigens with Biological E’s experience as a leading Asian vaccine manufacturer. "A safe and effective high-standard Japanese Encephalitis vaccine for adults and in particular children in the endemic areas throughout Asia will meet a high medical need", states Gerd Zettlmeissl, Chief Operating Officer of Intercell AG.
"This agreement with a leading Asian vaccine manufacturer leverages the commercialization of our Japanese Encephalitis vaccine and will be another step in our efforts to continue to develop and commercialize our broad portfolio of vaccine candidates and technologies". Dr. Vijay Kumar Datla, Chairman and Managing Director of Biological E. Limited added: "We are excited about this partnership with Intercell that enables us to offer a novel and safe vaccine to combat Japanese Encephalitis. There is an urgent need to respond to this epidemic throughout India and Asia where large-scale immunization is critical. Our partnership furthers the aim of ensuring a sustainable supply at the earliest."
